Gilead Sciences
GILD
1,463 hedge funds and large institutions have $64.4B invested in Gilead Sciences in 2019 Q3 according to their latest regulatory filings, with 94 funds opening new positions, 581 increasing their positions, 601 reducing their positions, and 99 closing their positions.
0.25% less ownership
Funds ownership: 80.61% → 80.36% (-0.25%)
3% less repeat investments, than reductions
Existing positions increased: 581 | Existing positions reduced: 601
5% less first-time investments, than exits
New positions opened: 94 | Existing positions closed: 99
1% less funds holding
Funds holding: 1,483 → 1,463 (-20)
8% less capital invested
Capital invested by funds: $70.3B → $64.4B (-$5.9B)
12% less funds holding in top 10
Funds holding in top 10: 49 → 43 (-6)
30% less call options, than puts
Call options by funds: $797M | Put options by funds: $1.14B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$348M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$243M |
| 3 |
Capital International Investors
Los Angeles,
California
|
+$146M |
| 4 |
Renaissance Technologies
New York
|
+$130M |
| 5 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$109M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$324M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$292M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
-$147M |
| 4 |
Millennium Management
New York
|
-$142M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$119M |
GILD Hedge Fund Activity: Q3 2019 in Review
1,463 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q3 2019, worth a combined $64.4B — down 8.4% from $70.3B a quarter earlier.
Sellers outnumbered buyers: 99 funds closed out of GILD and 94 opened new positions — a net loss of 5 holders — while 601 trimmed existing stakes and 581 added.
The largest buyer was Federated Hermes, adding an estimated $348M. The largest seller was Capital Research Global Investors, cutting an estimated $324M.
- 1,463 institutional investors held Gilead Sciences (GILD) as of Q3 2019, down from 1,483 in Q2 2019.
- Funds reported $64.4B of Gilead Sciences stock for Q3 2019, down 8.4% quarter-over-quarter.
- 94 funds opened new Gilead Sciences positions in Q3 2019 and 99 closed out, a net change of -5 holders.
- The largest Gilead Sciences buyer in Q3 2019 was Federated Hermes, an estimated $348M added.
- The largest Gilead Sciences seller in Q3 2019 was Capital Research Global Investors, an estimated $324M sold.
Based on aggregated 13F filings for Q3 2019.